The intelligence layer for uncompromising biopharma teams

DrugBank's Knowledge Graph is the connected intelligence core built from 20 years of curated biomedical data. Every datapoint traces back to its source, updates continuously, and is ready for AI and human discovery.

Book a Demo

150M+ data points.: Twenty years of curated biomedical data, structured so a scientist and an agent get the same answer from the same question.
Billions of directional relationships.: The graph records a relationship's direction, not just that a connection exists. Inhibiting and inducing aren't the same.
Causal links, not co-occurrence.: Terms are connected when a mechanism is real, not because terms appear together in an abstract, a distinction most graphs skip.
Pipeline coverage of 9,000+ companies.: Every asset, phase, and sponsor is tied to the underlying biology, so commercial and scientific context show up in one query.
Traceable to primary source.: Every datapoint carries its evidence lineage, so the answer holds up when your VP, your partner, or a regulator asks where it came from.
Engineered to close the gaps.: Relationships are built in-house to fill the curation gaps left by the industry that stall hard and complex queries.

Explore with confidence. Decide with conviction.

One connected graph means completeness is guaranteed, not assumed.

Trust that whitespace is a finding, not missing data
Explore the complete scientific and commercial picture
Make go/no-go calls based on the full landscape

20-year
track record: 1,500+
institutions: 65,000+
citations: $10B+
in research enabled: 10/20
top pharma companies

Knowledge Engine

Intelligence this nuanced isn't built overnight

Run continuously and overseen by expert curators, the Knowledge Engine delivers complete, correct, fresh, and traceable data directly to the graph.

Capture & Ingest

Continuous data point ingestion from a broad set of primary and regulatory sources

Engineer & Structure

Aggregate, harmonize, and resolve entities to a single record and connect to 20+ ontologies

Validate & Review

Ongoing quality control overseen by biostatisticians to maintain standards for millions of records

Engineered beyond the industry's blind spots

Sponsors resolved to their true owner

A sponsor's name on a filing isn't always who's behind it, and untangling that takes more than one lookup.

One company can rename itself multiple times over a trial's history.
One name can front a dozen affiliates, each filing under a different label.

Trial registries only ever show a piece of this. DrugBank pulls the rest from SEC filings, corporate registries, and M&A records, then normalizes and connects them, drawing on SEC records that reach back over a century.

Full structure for every indication

On-label, off-label, or investigational only tells you the regulatory status. It doesn't tell you how it actually works.

Every indication carries its own dose, region, patient population, and combination use, and none of that shows up in a status label.
Diseases don't exist in isolation, and the relationships between them matter as much as the indication itself.

DrugBank builds its own disease ontologies, designed for how indications actually vary, then maps the relationships between them. That structure makes it possible to pull the full indication record and filter or aggregate those fields directly.

REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

Across 8 trials

NASH - Nonalcoholic Steatohepatitis Non-alcoholic Steatohepatitis Non-Alcoholic Fatty Liver Disease MASH - Metabolic Dysfunction-Associated Steatohepatitis MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease + 2 more spellings

Metabolic Dysfunction-associated Steatohepatitis (MASH)

adjunct_therapy_in_treatment_of

	Indication 1	Indication 2
Condition	Advanced Liver Fibrosis	moderate Liver Fibrosis
Associated with	Metabolic Dysfunction-associated Steatohepatitis (MASH)	Metabolic Dysfunction-associated Steatohepatitis (MASH)
Excludes	Decompensated Cirrhosis	Decompensated Cirrhosis
Given with	Diet, Exercise	Diet, Exercise
Population	adult	adult
Region	US	US

Get started with DrugBank

Biopharma OS

Evaluate targets and assets with conviction

Deeply connected scientific and commercial data across drugs, targets, trials, diseases, companies, and more. Accessible via API, MCP, or the Workspace.

Biopharma OS

Clinical API

Empower better health decisions

Integrate structured drug information, drug-drug interactions, and more into your healthcare software to improve patient outcomes and clinical decision support.